View source for AMNOG

The '''Arzneimittelmarkt-Neuordnungsgesetz'''  ('''AMNOG''', English translation: "Pharmaceuticals Market Reorganisation Act") is a German law relating to the marketing of [[pharmaceutical]] products in [[Germany]]. It requires drug manufacturers to submit evidence to the [[Federal Joint Committee (Germany)]] that shows whether their new products have an added benefit compared to previous products.<ref>{{cite web|url=http://www.gkv-spitzenverband.de/english/statutory_health_insurance/amnog___evaluation_of_new_pharmaceutical/amnog___evaluation_of_new_pharmaceutical_1.jsp|title=AMNOG - evaluation of new pharmaceutical|publisher=GKV-Spitzenverband|year=2014|accessdate=27 May 2014|archive-url=https://archive.today/20140527190330/http://www.gkv-spitzenverband.de/english/statutory_health_insurance/amnog___evaluation_of_new_pharmaceutical/amnog___evaluation_of_new_pharmaceutical_1.jsp|archive-date=2014-05-27|url-status=dead}}</ref> It is credited with reducing the cost of healthcare in Germany.<ref>{{cite web|url=https://www.theatlantic.com/health/archive/2014/05/why-medicine-is-cheaper-in-germany/371418/|title=Why Medicine Is Cheaper in Germany|author=Olga Khazan|date=22 May 2014|publisher=The Atlantic}}</ref>
== References ==
{{reflist}}
== See also ==
* [[Healthcare in Germany]]
* [[Institute for Quality and Efficiency in Health Care]]
[[Category:Health law in Germany]]
[[Category:Drug development]]
{{Germany-law-stub}}